Valneva Stock Falls as Drug Regulator Seeks Data on Covid Shot
This article is for subscribers only.
Valneva SE shares slumped after the French company said Europe’s drug regulator had asked for more information on its Covid-19 vaccine.
The stock fell as much as 17% in early trading Monday, the steepest intraday decline since Jan. 19, after the European Medicines Agency’s evaluating panel asked for additional data and further justification for conditional marketing authorization for the shot.